Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Harold Atkins"'
Autor:
Anubhav Agarwal, Natasha Kekre, Harold Atkins, Haris Imsirovic, Brian Hutton, Doug Coyle, Kednapa Thavorn
Publikováno v:
Current Oncology, Vol 31, Iss 8, Pp 4192-4208 (2024)
Hematologic cancers, notably leukemias and lymphomas, pose significant challenges to healthcare systems globally, due to rising incidence rates and increasing costs. This study aimed to estimate the phase and lifetime health system total costs (not n
Externí odkaz:
https://doaj.org/article/dbedf495b94a4bbc83b3a74e86e29aee
Autor:
Manoj M. Lalu, Natasha Kekre, Joshua Montroy, Maryam Ghiasi, Kevin Hay, Scott McComb, Risini Weeratna, Harold Atkins, Brian Hutton, Ayel Yahya, Ashish Masurekar, Mohamad Sobh, Dean A. Fergusson
Publikováno v:
Systematic Reviews, Vol 12, Iss 1, Pp 1-7 (2023)
Abstract Background Chimeric antigen receptor T cell therapy (CAR-T) represents a promising and exciting new therapy for hematologic malignancies, where prognosis for relapsed/refractory patients remains poor. Encouraging results from clinical trials
Externí odkaz:
https://doaj.org/article/e178a854e819485ba2fe09dae90e30a0
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Chimeric antigen receptor (CAR) T-cells are an emerging therapy for the treatment of relapsed/refractory B-cell malignancies. While CD19 CAR-T cells have been FDA-approved, CAR T-cells targeting CD22, as well as dual-targeting CD19/CD22 CAR T-cells,
Externí odkaz:
https://doaj.org/article/e7e328e2355f43348796f7b3acd4eeaa
Autor:
Natasha Kekre, Kevin A. Hay, John R. Webb, Ranjeeta Mallick, Miruna Balasundaram, Mhairi K. Sigrist, Anne-Marie Clement, Julie S. Nielsen, Jennifer Quizi, Eric Yung, Scott D. Brown, Lisa Dreolini, Daniel D. Waller, Julian Smazynski, Nicole S. Gierc, Bianca C. Loveless, Kayla Clark, Tyler Dyer, Richard Hogg, Leah McCormick, Michael Gignac, Shanti Bell, D. Maria Chapman, David Bond, Siao Yong, Rachel Fung, Heather M. Lockyer, Victoria Hodgson, Catherine Murphy, Ana Subramanian, Evelyn Wiebe, Piriya Yoganathan, Liana Medynski, Dominique C. Vaillan, Alice Black, Sheryl McDiarmid, Michael Kennah, Linda Hamelin, Kevin Song, Sujaatha Narayanan, Judith A. Rodrigo, Stefany Dupont, Terry Hawrysh, Justin Presseau, Kednapa Thavorn, Manoj M. Lalu, Dean A. Fergusson, John C. Bell, Harold Atkins, Brad H. Nelson, Robert A. Holt
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Access to commercial CD19 CAR-T cells remains limited even in wealthy countries like Canada due to clinical, logistical, and financial barriers related to centrally manufactured products. We created a non-commercial academic platform for end-to-end m
Externí odkaz:
https://doaj.org/article/ba9bb5ccb69a4646aee78f29aa8e0137
Autor:
Russell Sterrett, Amarilis Figueiredo, Ranjeeta Mallick, Natasha Kekre, Harold Atkins, Arleigh McCurdy
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss 4, Pp 437-442 (2021)
There have been significant improvements in therapeutic options for relapsed multiple myeloma (MM) over the past two decades, with many novel agents including proteasome inhibitors, immunomodulatory agents, and more recently monoclonal antibodies dem
Externí odkaz:
https://doaj.org/article/855b6e849f604315b0e9b1d6256a2e6b
Autor:
Gisell Castillo, Manoj Lalu, Sarah Asad, Madison Foster, Natasha Kekre, Dean Fergusson, Terry Hawrysh, Harold Atkins, Kednapa Thavorn, Joshua Montroy, Stuart Schwartz, Robert Holt, Raewyn Broady, Justin Presseau, on behalf of the GO CART team
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-13 (2021)
Abstract Background Novel therapies often fail to reach the bedside due to low trial recruitment rates. Prior to conducting one of the first chimeric antigen receptor (CAR) T cell therapy trials in Canada, we used the Theoretical Domains Framework, a
Externí odkaz:
https://doaj.org/article/430aa40df7a447f89b64632aa30c865a
Publikováno v:
Systematic Reviews, Vol 10, Iss 1, Pp 1-8 (2021)
Abstract Background Chimeric antigen receptor (CAR) T cell therapy has had great success in treating patients with relapsed or refractory B cell malignancies, with CD19-targeting therapies now approved in many countries. However, a subset of patients
Externí odkaz:
https://doaj.org/article/72d0b63417d24104b524ce5b965f5245
Autor:
Madison Foster, Dean A Fergusson, Terry Hawrysh, Justin Presseau, Natasha Kekre, Stuart Schwartz, Gisell Castillo, Sarah Asad, Grace Fox, Harold Atkins, Kednapa Thavorn, Joshua Montroy, Robert A Holt, Zarah Monfaredi, Manoj M Lalu
Publikováno v:
Research Involvement and Engagement, Vol 6, Iss 1, Pp 1-10 (2020)
Abstract Aim Though patient engagement in clinical research is growing, recent reports suggest few clinical trials report on such activities. To address this gap, we describe our approach to patient engagement in the development of a clinical trial p
Externí odkaz:
https://doaj.org/article/41291d56e02947a0aa68b46ceb1c3cfe
Autor:
Manoj M Lalu, Ian D Graham, Justin Presseau, Kelvin KW Chan, Daniel A Ollendorf, Natasha Kekre, Terry Hawrysh, Harold Atkins, Doug Coyle, Mackenzie Wilson
Publikováno v:
BMJ Open, Vol 11, Iss 8 (2021)
Introduction Chimeric antigen receptor T-cell (CAR-T) therapy is a class of immunotherapy. An economic evaluation conducted at an early stage of development of CAR-T therapy for treatment of adult relapsed or refractory acute lymphoblastic leukaemia
Externí odkaz:
https://doaj.org/article/915e75e5d8294f2a8b074fbb15d2e62b
Autor:
Amarilis Figueiredo, Rabih Kassis, Rashed Albacker, Arleigh McCurdy, Natasha Kekre, Harold Atkins
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 41, Iss 4, Pp 285-291 (2019)
While first-line induction therapy for patients with multiple myeloma has changed over the years, autologous hematopoietic stem cell transplantation still plays a significant role, improving both depth of response and progression-free survival of mye
Externí odkaz:
https://doaj.org/article/738302727bc645d5a814bf1fb3cf4106